Physiomics PLC Project extension with global pharma company (7344B)
October 09 2015 - 1:00AM
UK Regulatory
TIDMPYC
RNS Number : 7344B
Physiomics PLC
09 October 2015
9 October 2015
Physiomics plc
("Physiomics") or ("the Company")
Update: 5(th) extension project to advance oncology candidate
with global pharma company
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology
company, is pleased to announce that it has signed a further
extension to a Virtual Tumour project with a major global
pharmaceutical company, first announced on 1(st) March 2012. The
extension will cover predicting optimal regimens for a candidate
compound and should be completed by the end of 2015.
The project will be performed on a fee-for-service basis.
Dr Mark Chadwick, CEO of Physiomics, commented:
"We are very pleased to have extended this collaboration once
more, demonstrating the importance of Virtual Tumour to their drug
discovery and development projects. This collaboration seems likely
to continue well into the future."
The Company also anticipates announcing an additional, new
Virtual Tumour deal shortly.
Enquiries:
Physiomics plc
Dr Mark Chadwick, CEO
+44 (0)1865 784 980
WH Ireland Limited (broker/nomad)
Katy Mitchell
+44 (0) 161 832 2174
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services
company applying simulations of cell behaviour to drug development
to reduce the high attrition rates of clinical trials. 80-90 per
cent of all clinical drug candidates fail to reach the market and
estimates show that an overall ten per cent improvement in success
rates could reduce the cost of one drug's development by as much as
$242 million, from the current estimate of around $800 million(1)
.
Physiomics develops computational systems biology models to
predict and understand cancer drug efficacy from pre-clinical
research to clinical development. Physiomics has created detailed
mathematical models incorporating the most important molecular
events taking place during the human cell cycle and apoptosis
processes. The company's SystemCell(R) technology enables the
simulation of populations of "virtual cells". The company has also
developed a "Virtual Tumour" model to simulate the effect of
anti-cancer drugs on tumour growth. The models are used to optimise
compound design and to design drug schedules and combination
therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and
floated on AIM in 2004. For further information, please visit
www.physiomics-plc.com
SystemCell(R) is a registered trademark of Physiomics plc
(1) Tufts Centre Impact Report 2002
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUGGAGUUPAGQR
(END) Dow Jones Newswires
October 09, 2015 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024